MedDataX Logo

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers

NCT ID: NCT00387569

Last Updated: 2008-05-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

99 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to assess the safety of an investigational meningitis vaccine in toddlers and their immune response to it.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents

NCT00387725

Healthy
COMPLETED PHASE2

Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

NCT00297687

Meningitis, Meningococcal
COMPLETED PHASE1

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

NCT02534935

Meningococcal B Disease
COMPLETED PHASE2

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

NCT00808028

Meningitis, Meningococcal
COMPLETED PHASE2

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

NCT01352793

Meningitis, Meningococcal
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Experimental (20ug); Active Comparator/Placebo

Group Type EXPERIMENTAL

MnB vaccine rLP8026

Intervention Type BIOLOGICAL

MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)

Cohort 2

Experimental (60ug); Active Comparator/Placebo

Group Type EXPERIMENTAL

MnB vaccine rLP8026

Intervention Type BIOLOGICAL

MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)

Cohort 3

Experimental (200ug); Active Comparator/Placebo

Group Type EXPERIMENTAL

MnB vaccine rLP8026

Intervention Type BIOLOGICAL

MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MnB vaccine rLP8026

MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)

Intervention Type BIOLOGICAL

MnB vaccine rLP8026

MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)

Intervention Type BIOLOGICAL

MnB vaccine rLP8026

MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18- to 36-months
* Healthy male or female subjects

Exclusion Criteria

* Prior vaccination with a serogroup B meningococcal vaccine
* Prior history of any invasive meningococcal disease
Minimum Eligible Age

18 Months

Maximum Eligible Age

36 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wyeth

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Wyeth is now a wholly owned subsidiary of Pfizer

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Australia, [email protected]

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Perth, Western Australia, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

6108A1-502

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults
NCT00780806 COMPLETED PHASE1/PHASE2
Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults
NCT00879814 COMPLETED PHASE1
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
NCT01830855 COMPLETED PHASE3
A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years
NCT01299480 COMPLETED PHASE2
Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants
NCT00798304 TERMINATED PHASE2
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
NCT02531698 COMPLETED PHASE2
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
NCT01352845 COMPLETED PHASE3
A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.
NCT01323270 COMPLETED PHASE2
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
NCT01543087 COMPLETED PHASE3
A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants
NCT04645966 TERMINATED PHASE2
Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years
NCT01423084 COMPLETED PHASE3
Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age
NCT01768117 COMPLETED PHASE2
Combined Study - Phase 3b MenB Long Term Persistence in Adolescents
NCT02446743 COMPLETED PHASE3
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age
NCT01461980 COMPLETED PHASE2
Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
NCT00381615 COMPLETED PHASE2
A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine
NCT04689191 UNKNOWN PHASE3
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
NCT01339923 COMPLETED PHASE3
Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old
NCT00196976 COMPLETED PHASE2
Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants
NCT00433914 COMPLETED PHASE2
A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine
NCT02481232 UNKNOWN PHASE1
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12
NCT00944034 COMPLETED PHASE2/PHASE3
Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers
NCT00631995 COMPLETED PHASE1
A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine
NCT04689165 UNKNOWN PHASE3
A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India
NCT01086969 COMPLETED PHASE3
Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)
NCT06314880 RECRUITING PHASE1